| Name | Renalytix (Reg S) |
|---|---|
| Epic | RENX |
| Isin | GB00BYWL4Y04 |
| Industry | Medical Equipment and Services |
| Latest share price | 7.07p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £13.43 | Debt ratio | n/a |
| Shares in issue | 154.37 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -760.58 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -56 | 52-week high / low | 7.07p / 50.40p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Renalytix (Reg S) |
|---|---|
| Address | 2 Leman Street, London, United Kingdom, E1W 9US |
| Telephone | |
| Website | http://www.renalytix.com/ |
| Director | Position |
|---|---|
| Mr James Renwick McCullough | CEO |
| Mr Daniel J. Levangie | Non-Executive Director |
| Mr Erik Kristian Lium | Non-Executive Director |
| Ms Catherine Coste | Non-Executive Director |
| Mr Christopher H B Mills | Non-Executive Chairman |
| Mr Fergus Fleming | Chief Technical Officer |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 30/06/23 | 30/06/22 | 30/06/21 |
| Intangible asssets and goodwill | 12.51 | 14.02 | 18.02 |
| Investments and other non-current assets | n/a | 0.01 | n/a |
| Total non-current assets | 13.78 | 15.83 | 26.57 |
| Inventory / work in progress | 0.72 | 1.16 | 0.35 |
| Trade and other receivables | 0.78 | 0.9 | 1.11 |
| Cash and equivalents | 24.68 | 41.33 | 65.16 |
| Other current assets and asset held for resale | 2.16 | 4.04 | 9.38 |
| Total of all assets | 42.12 | 63.26 | 102.58 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 16.13 | 12.2 | 7.26 |
| Long term liabilities | 7.53 | 7.88 | 0.21 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 23.66 | 20.09 | 7.48 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 18.45 | 43.17 | 95.1 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.3 | 0.24 | 0.23 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -99.18 | -52.96 | 3.77 |
| Share premium account | 104.95 | 85.44 | 76.46 |
| Total equity | 18.45 | 43.17 | 95.1 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -42.35 | -57.37 | -32.61 |
| Pre-tax profit | -46.22 | -49.63 | -35.79 |